Observations

Citizens came out to speak to board members about cannabis labeling, collaboration with medical cannabis patients, and pesticide use.

Medically compliant products, the penalty matrix for traceability violations, and financier vetting were debated by the Board.

The Board considered feedback from stakeholders about budtender permits and looked at cannabis testing lab accreditation.

Board Member Ollie Garrett talked about agency enforcement practices and research into minority ownership of cannabis licenses.

The Board and staff engaged in a lengthy dialogue around the new CR-101 on quality assurance testing and product requirements.

Two CR-102's were approved with draft rule changes to implement 2017 and 2018 cannabis legislation.

The team engaged in a discussion around rule changes for cannabidiol (CBD) additives to I-502 products.

The hidden ownership amnesty program proposal was put on hold, plus a quarterly licensing update.

A CR-101 for Cannabis Quality Assurance Testing and Products Requirements was adopted before the Board heard public comments.

Board members prepared to open rulemaking on cannabis testing requirements and medical products, and will hire a staffer to update licensee demographic information.